His381 of the rat CCKB receptor is essential for CCKB versus CCKA receptor antagonist selectivity

https://doi.org/10.1016/0014-2999(95)00676-1Get rights and content

Abstract

A great interest is devoted to antagonists of the cholecystokinin type B (CCKB) receptor such as L-365,260, which reduces panic attacks in humans and to antagonists of the cholecystokinin type A (CCKA) receptor, such as L-364,718 which might be efficient in mental diseases. The A/B specificity of these antagonists was proposed to be mainly dependent on the amino acid sequence of the seventh transmembrane domain (Mantamadiotis and Baldwin (1994) Biochem. Biophys. Res. Commun. 201, 1382). In our study, one of these residues, His381 was replaced in the rat CCKB receptor by leucine (the corresponding residue in the CCKA receptor), phenylalanine or arginine using site-directed mutagenesis. Changing histidine for leucine or phenylalanine did not modify significantly the affinity of the CCKB receptor antagonists, L-365,260 and PD-134,308 although both compounds belong to different chemical classes, but strongly improved the affinity of the CCKA receptor antagonists tested. Interestingly, the A selectivity of these CCKA receptor antagonists was recovered by substituting His381 by arginine. Moreover, these results are discussed on the basis of a three dimentional model of the CCKB receptor. The mutated receptors possessed unchanged binding properties for agonists, suggesting that determinants confering specificity for agonists and antagonists are different.

References (40)

  • T. Mantamadiotis et al.

    The seventh transmembrane domain of gastrin/CCK receptors contributes to non peptide antagonist binding

    Biochem. Biophys. Res. Commun.

    (1994)
  • G.A. McPherson

    A practical computer based approach to the analysis of radioligand binding experiments

    Comput. Methods Programs Biomed.

    (1983)
  • T.H. Moran et al.

    Two brain CCK receptors: implications for behavioral action

    Brain Res

    (1986)
  • J. Nathans et al.

    Isolation, sequence analysis, and intron-exon arrangement of the gene encoding bovine Rhodopsin

    Cell

    (1983)
  • M.E. Olah et al.

    Cloning, expression, and characterization of the unique bovine A1 adenosine

    J. Biol. Chem.

    (1992)
  • J.R. Pisegna et al.

    Molecular cloning of the human brain and gastric cholecystokinin receptors: structure, functional expression and chromosomal localization

    Biochem. Biophys. Res. Commun.

    (1992)
  • R.A. Shapiro et al.

    A deletion mutation in the third cytoplasmic loop of the mouse m1 muscarinic acetylcholine receptor unmask cryptic G protein binding site

    J. Biol. Chem.

    (1993)
  • D.J. Underwood et al.

    Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor

    Chem. Biol.

    (1994)
  • M. Beinborn et al.

    A single amino acid of the cholecystokinin B/gastrin receptor determines specificity for non peptides antagonists

    Nature

    (1993)
  • D. Bownds

    Site of attachment of retinal in rhodopsin

    Nature

    (1967)
  • Cited by (33)

    • Molecular basis for binding and subtype selectivity of 1,4-benzodiazepine antagonist ligands of the cholecystokinin receptor

      2012, Journal of Biological Chemistry
      Citation Excerpt :

      Selective, small molecule ligands have been developed for both CCK1R and CCK2R (22, 23). It is now clear, based on limited receptor mutagenesis, photoaffinity labeling, and pharmacological manipulations, that these ligands bind to an allosteric site within the intramembranous helical bundle that is distinct from the orthosteric CCK peptide-binding site of the CCK1R (24–27). However, the molecular basis for ligand selectivity between the two subtypes of CCK receptors remains unclear.

    • Evidence that interspecies polymorphism in the human and rat cholecystokinin receptor-2 affects structure of the binding site for the endogenous agonist cholecystokinin

      2005, Journal of Biological Chemistry
      Citation Excerpt :

      This is likely the result of an increase of the collective contribution of other residues, such as His376, Met67, Cys107, and Phe110, to the binding site of the human CCK2R. This view fully agrees with previous mutagenesis data showing that exchange of His376 for a leucine decreased the affinity of CCK8 for the human CCK2R by 30-fold, whereas mutation of the corresponding amino acid in the rat CCK2R did not affect CCK8 recognition (19, 21). Thereafter, we demonstrated that different contributions of His207 in human versus rat CCK2R were likely not due to different protonated states.

    • Conformational and molecular modeling studies of sulfated cholecystokinin-15

      2002, Biochemical and Biophysical Research Communications
    • Activation of phospholipase C by cholecystokinin receptor subtypes with different G-protein-coupling specificities in hormone-secreting pancreatic cell lines

      2000, Biochemical Pharmacology
      Citation Excerpt :

      Surprisingly, the affinity for [3H]L-365,260 was in the same low nM range, which is in contrast to what is generally accepted for the CCKB ligand. To our knowledge, this ligand has never been used in this cell line; hence, comparison to the affinity obtained in COS cells transfected with the CCKB receptor gene (Ki of about 3 nM [39] and ic50 of 2–6 nM [40]) should be made with caution. It bears mentioning that our initial approach, i.e. the use of iodinated CCK-8 as ligand, failed to yield reproducible results and therefore was abandoned in favor of the tritiated ligands.

    View all citing articles on Scopus
    View full text